

# Nordic-Baltic Conference in Pharmacovigilance

2 June 2026, Stockholm

## Program

**Conference moderators:** Sara Maxe, Maxe Pharma Consulting and Patricia Jimenez Vasquez, MSD

09.00 Registration

### 09.30 Welcome and practical information

Läkemedelsakademin and moderators

### 09.45 Keynote lecture Decisions that Matter: Real Life impact of drug safety work

Felix Arellano, Roche

### 10.15 Session: AI in Pharmacovigilance from authority and industry perspective

#### AI Tools for PV at the Swedish Medical Products Agency

Luise Dürlich, Swedish Medical Products Agency

#### Applications of AI in PV: from Transactional tasks in Case handling and Periodic reporting to Multimodal Predictive Clinical Safety models during Drug development

Magnus Nord, AstraZeneca

Coffee break

### Trusted use of AI in Pharmacovigilance

Vijay Kara, GSK

#### Discussion

Luise Dürlich, Swedish Medical Products Agency; Magnus Nord, AstraZeneca; Vijay Kara, GSK; Julia Appelskog, CSL

Lunch break

### 13.15 Session: The PV role in small vs big company – global environment vs affiliate – how to bridge similarities and benefit from the differences

#### From PV Macroformat to Microformat: Leveraging Differences, Building on Similarities

Karin Kempe, Karo Healthcare

#### Global Vision Meets Local Reality: Pharmacovigilance in Small Companies, Big Pharma, and Affiliates

Julia Appelskog, CSL

#### Discussion

All session speakers

### 14.15 Session: To transform EMA decisions into local practices

#### Risk minimisation materials – from PRAC – discussion to national implementation – a regulatory perspective

Ulla Wändel Liminga, MPA Sweden and PRAC

Coffee break

### Effectiveness of risk minimisation measures to prevent pregnancy exposure: an example of mycophenolate use in women of childbearing age in Estonia

Katrin Kurvits, State Agency of Medicines, Estonia

### The national agency's experience in approving digital communication tools in addition to the regular channels used for dissemination of educational materials – additional risk minimisation measures

Lina Masionienė, State Medicines Control Agency of Lithuania

#### Discussion

All session speakers

### 15.45 Session: News from Regulators & a Future outlook

#### Local novelty in pharmacovigilance

Liene Luce, State Agency of Medicines, Latvia

#### Farmasto – how to support rational use of medicines through reliable high-quality medicines information

Johanna Seppänen, Fimea, Finland

#### Discussion Future of PV

Felix Arellano, Roche; Ulla Wändel Liminga, MPA Sweden and PRAC; Julia Appelskog, CSL; Johanna Seppänen, Fimea; Liene Luce, State Agency of Medicines, Latvia

### 16.50 – 17.00 Closing

Moderators